Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


SHS invests in laboratory equipment manufacturer Biontis


P R E S S R E L E A S E

• Founder Dr. Andreas Zucker remains the principal shareholder
• International expansion planned
• KfW a co-investor

Tübingen, Germany, July 14, 2008 – Funds from Tübingen-based growth investor SHS Gesellschaft für Beteiligungsmanagement are investing in Biontis GmbH in Geesthacht (near Hamburg) within the framework of an increase of capital. The company has its sights set on strong growth and international expansion with the aid of this venture capital investor. Biontis GmbH has developed fully automated processes for biochemical analysis of complex liquid mixtures, which it markets in Germany and neighboring countries. The applications for this technology include laboratories for water analysis and food inspections, forensic medicine as well as clinical diagnostics.

Chemist Andreas Zucker, who formed the company in the year 2002, will continue to be the majority shareholder and chief executive officer of Biontis GmbH. In addition to SHS, KfW Mittelstandsbank is also investing in this company as a co-investor through the ERP Start-up Fund.

“Our investment in Biontis is classical growth financing. Andreas Zucker and his team have developed and brought to market highly innovative biochemical laboratory analysis equipment. The task now is market these products internationally and to successfully shape the company’s planned growth. We will be supporting Andreas Zucker and his team to the best of our abilities,” is the way Hubertus Leonhardt, a partner in SHS Gesellschaft für Beteiligungsmanagement, comments on the investment in Biontis GmbH.

“There is already demand today for our products in Germany and beyond. With SHS Gesellschaft für Beteiligungsmanagement and KfW, we have now found two financially strong partners whose assistance will enable us to systematically implement our expansion strategy. We are optimally aligned for moving into further markets, for example,” notes Biontis founder Andreas Zucker with respect to these venture capital investments.

Andreas Zucker, who holds a doctorate in chemistry, formed Biontis GmbH in the year 2002 in the town of Geesthacht in the state of Schleswig-Holstein. Previous to that, he had built and managed the research and development operation at Bio-Rad Laboratories in Munich for more than five years.

Biontis GmbH today already has various marketable chemical analysis products in the fields of clinical diagnostics, food analysis, environmental analysis, pharmaceutical research, quality control and forensic medicine. These systems-based solutions consist of chemical processes and the matching optimized automation. The modularly designed Enviro, Aqua and Medicus quick samplers are capable of very quickly and fully automatically preparing liquids with complex compositions in order to enable one or more sought constituents to then be swiftly analyzed. This affords users a very major advantage in terms of speed, as well as significantly lower costs.

“We are delighted to be able to accompany the growth of this innovative company,” says Hubertus Leonhardt. The investment in Biontis GmbH is the first investment that SHS Gesellschaft für Beteiligungsmanagement has made since the first closing of its SHS Fund III in April of this year.

Investors from Germany and Europe brought €40 million to the first closing of this third fund to be launched by Tübingen-based SHS Gesellschaft für Beteiligungsmanagement. These investors include the European Investment Fund (EIF), through which the SHS Fund is receiving support from the ERP-EIF umbrella fund and from the European Union’s “Competitiveness and Innovation Framework Programme” (CIP), as well as Kreditanstalt für Wiederaufbau (KfW), a pension fund, the Fund of Funds, along with various entrepreneurs, family asset management organizations and the SHS management team, itself. SHS will include further investors in the Fund within the framework of its second closing.

Like its predecessor funds, SHS Fund III will be investing in attractive companies that have marketable products in the field of food sciences. With its successful investments in companies like VITA 34, ProBioGen and Novosis, SHS has a proven track record as a seasoned expansion specialist whose fields of activity include the Life Sciences.

SHS will be investing its new Fund in fields that offer fast and substantial growth opportunities for young, innovative companies. In particular, this includes medical technology and supplies, as well as diagnostic, platform and production technologies. SHS invests exclusively in companies with marketable products and technologies. In addition to providing capital to its portfolio companies, the seasoned SHS team also contributes management expertise and resources for corporate development and expansion.

About SHS Gesellschaft für Beteiligungsmanagement mbH
Established in Tübingen, Germany, in 1993, SHS Gesellschaft für Beteiligungsmanagement specializes in financing and advising young companies in forwardlooking sectors, especially Healthcare and Life Sciences. SHS currently has around €120 million in investment capital under management in its existing funds. Its principal shareholders are former McKinsey consultants Bernhard Schirmers and Reinhilde Spatscheck, as well as Hubertus Leonhardt, who had previously been a corporate finance project manager with Arthur Andersen.

Further information is available from:
Simon Baumann
IRA WÜLFING KOMMUNIKATION
t: +49.(0)89. 2000 30-32
f: +49.(0)89. 2000 30-40
simon.baumann@wuelfing-kommunikation.de


Publisher Contact Information:

IRA WÜLFING KOMMUNIKATION
+49.(0)89. 2000 30-32
simon.baumann@wuelfing-kommunikation.de

Company profile of SHS Gesellschaft für Beteiligungsmanagement
Past press releases of SHS Gesellschaft für Beteiligungsmanagement.

Data


25,894
Tech investments
From our Online Data Service
16,759
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jun 29€1.3MSecurity
Jun 28€2.2MDatabase
Jun 28€12.0MMaterials
Jun 28€5.5MBusiness applications
Jun 27€3.0MBiopharmaceuticals
Jun 27€10.0MEnergy related
Jun 27N/AWireless applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.